See the DrugPatentWatch profile for Remimazolam
Remimazolam – a quick‑acting, short‑duration benzodiazepine
| Item | What you need to know |
|------|-----------------------|
| Brand name(s) | Remifent™ (Japan), Remimazolam besylate (US/Canada), and other brand names in China, Russia, and other markets. |
| Drug class | Intravenous (IV) benzodiazepine hypnotic. |
| Primary indication | 1. Procedural sedation (e.g., endoscopy, minor surgery). 2. General anesthesia (in Japan) and in the U.S. for short‑duration procedures. |
| Mechanism | Positive allosteric modulation of the GABA‑A receptor; onset < 1 min, duration of effect < 10 min, metabolized by non‑enzymatic amidation to an inactive metabolite. |
| Why it’s gaining traction | Fast onset, rapid recovery, very low incidence of hypotension or respiratory depression compared with propofol; no accumulation with repeated doses. |
| Regulatory timeline | • Japan – Approved 2018 (J-DOI, “Remifent™”).
• U.S. FDA – Approved 2023 for procedural sedation (Remimazolam besylate).
• Europe – EMA review pending; some countries (e.g., Germany, France) have approved under a conditional marketing authorisation for specific indications (still awaiting full approval).
• China, Russia, Taiwan – Approved 2021‑2022 for procedural sedation. |
| Manufacturers / Commercial Partners | • Kyowa Kirin – global commercial rights.
• Santen Pharma – Japanese partner for distribution.
• Cipla, Sandoz, and others have licensing agreements for generic production in select markets. |
| Pricing snapshot (2025) | US – Approximately $1,200–$1,400 per 2 mL vial (dose‑adjustable).
Japan – Roughly ¥10,000–¥12,000 (~$70–$85) per vial.
Europe – Similar to US levels once approved; generic entry expected 2027‑2028 at 30–50 % discount. |
| Reimbursement | • U.S. – Covered by most private insurers; Medicare Part B reimbursement ~\$1,200 per procedure (variable).
• Japan – National health insurance includes a negotiated fee schedule of about ¥7,000 (≈ $60) for a standard sedation dose.
• EU – Reimbursement varies by country; many are still negotiating price‑list agreements. |
| Market size (2024–2026 projection) | • Global market for procedural sedatives ≈ $8–9 billion.
• Remimazolam is projected to capture 6–8 % of that share by 2028, translating to $500–$700 million annual revenue worldwide.
• Growth driven by increasing numbers of minimally invasive procedures and the preference for short‑acting agents in ambulatory surgery centers. |
| Competitive landscape | • Propofol (short‑acting but higher cardiovascular side‑effects).
• Midazolam + Fentanyl (slower onset, longer recovery).
• Dexmedetomidine (sedative‑analgesic but not benzodiazepine; slower onset).
• Emerging generics: Several companies are filing for generic approval in the U.S. and EU, expected 2027‑2028. |
| Key drivers of adoption | 1. Safety profile – minimal hypotension, no respiratory depression.
2. Rapid recovery – facilitates same‑day discharge.
3. Ease of titration – single‑dose vials, no infusion pumps needed for short procedures.
4. Guideline updates – many societies (ASA, ESICM) now recommend it as a first‑line agent for short procedures. |
| Barriers / challenges | • Higher cost than propofol and midazolam in many settings.
• Limited generic competition until 2027‑2028.
• Clinician familiarity – many anesthesiologists are more accustomed to propofol; training is required for optimal dosing and reversal with flumazenil (though reversal is rarely needed). |
---
How it’s being used in practice
| Setting | Typical dose | Administration | Recovery time |
|---------|--------------|----------------|---------------|
| Procedural sedation (endoscopy, colonoscopy) | 0.2–0.3 mg/kg IV (bolus) | Slow push over 30–60 s | 4–7 min to baseline consciousness |
| Short general anesthesia (≤ 30 min) | 0.2 mg/kg IV bolus + 0.04 mg/kg/min infusion | Continuous infusion after induction | 5–8 min after cessation |
| Adjunct to local/regional anesthesia | 0.1–0.2 mg/kg IV | Single bolus | < 5 min |
---
Reimbursement & payer landscape (U.S. snapshot)
| Payer | Typical reimbursement per vial | Comments |
|-------|--------------------------------|----------|
| Commercial insurers | $1,200–$1,400 | Negotiated fee‑for‑service; often bundled with procedure fee. |
| Medicare Part B | $1,200–$1,300 | Reimbursed under the “drug” category for anesthetic agents. |
| Medicaid | Variable by state | Some states cover at full cost, others at reduced rate; monitoring trends. |
---
Future outlook
| Year | Milestone | Market implication |
|------|-----------|--------------------|
| 2025 | First generic approval in U.S. | Price drop ~30 % for procedural sedation |
| 2026 | EMA full approval in EU for procedural sedation | Expansion into high‑volume European markets |
| 2027 | Expansion to pediatric sedation (under review) | New patient segment ~10 % of current volume |
| 2028 | Launch of combination product (remimazolam + opioid) | Potential to capture additional share in ICU sedation |
---
Bottom line
Remimazolam is carving out a niche as a fast‑onset, short‑acting, and well‑tolerated sedative for procedural and brief general anesthesia. Its market is still early but growing rapidly, especially in the U.S. and Japan. The key to its commercial success will be price competitiveness as generics enter, continued endorsement by anesthesia societies, and streamlined training for clinicians. If you’re a clinician or a pharmacy manager, keeping an eye on the 2027‑2028 generic rollout will help you plan inventory and budget adjustments.